NWPF

News ArchivesRead News

Presynaptic Dopaminergic Lesion Predicts Drug-Induced Dyskinesia

Thursday May 15, 2014

Medwire News - Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson’s disease (PD) will later develop levodopa-induced dyskinesia (LID).

Phil Lee (Yonsei University College of Medicine, Seoul, Korea) and colleagues studied 127 PD patients who underwent positron emission tomography at the time of diagnosis, before starting drug treatment.

They found that the larger the reduction patients had in dopamine transporter (DAT) uptake in the putamen at baseline, the higher was their risk of developing LID during an average 3.4 years of follow-up. This was true for the anterior, posterior and whole putamen after accounting for confounders, whereas DAT uptake in the caudate and ventral striatum did not predict LID.

When divided into tertiles based on DAT uptake, patients with moderate and severe reductions were respectively 2.97- and 3.47-fold more likely to develop LID relative to those with mild reductions.

The rate of LID in the whole cohort was 27.6% and the rate in those with mild DAT uptake reductions in the whole putamen was about 15% versus 50% in those with severe reductions.

In an editorial accompanying the study in Neurology, Peter LeWitt (Henry Ford Hospital, Bloomfield, Michigan, USA) and Maral Mouradian (Rutgers–Robert Wood Johnson Medical School, Piscataway, New Jersey, USA) say that the findings bring “presynaptic dopaminergic denervation into the forefront for explaining dyskinesia.”

However, they caution that there is as yet no “simple clinical message because of several confounding factors.”

These include a lower rate of dopaminergic agonist use among patients who developed LID, as well as a higher proportion of women. Patients with LID also had higher Unified Parkinson’s Disease Rating Scale scores at diagnosis and were taking a higher average daily levodopa dose.

Indeed, a higher levodopa dose was a significant predictor of LID on multivariate analysis, as was a younger age at PD onset.

“These confounding factors make it difficult to conclude how important the presynaptic dopaminergic lesion is, by itself, for developing LID”, conclude the editorialists.

(15 May 2014). Medwire News. Presynaptic Dopaminergic Lesion Predicts Drug-Induced Dyskinesia. http://www.medwirenews.com/454/105587/Parkinsons_disease/Presynaptic_dopaminergic_lesion_predicts_drug-induced_dyskinesia.html

Recent News

Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 9 - Parkinson’s Experiment to Be Aboard Next Flight to International Space Station
Aug 9 - Parkinson’s Disease and Sleeping with the Enemy
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement